PolyActiva and RareSight Inc. have announced a strategic collaboration to develop first-in-class therapies for rare pediatric retinal diseases that currently have no approved drug treatments. The research collaboration agreement, leveraging PolyActiva’s proprietary PREZIA™ platform, will offer first-of-its-kind, new chemical entity (NCE)-eligible pro-drug candidates to people affected by blinding eye conditions.